Regen BioPharma, Inc.(RGBP.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Regen BioPharma, Inc.
RGBP.US
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6.
1.944 T
RGBP.USMarket value -Rank by Market Cap -/-

Financial Score

26/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking174/397
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE22.16%A
    • Profit Margin-538.76%E
    • Gross Margin100.00%A
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY-90.72%E
    • Total Assets YoY70.49%A
    • Net Assets YoY-20.39%E
  • Cash ScoreD
    • Cash Flow Margin-18.56%D
    • OCF YoY0.00%C
  • Operating ScoreA
    • Turnover1.09A
  • Debt ScoreE
    • Gearing Ratio2387.16%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    [Opinion] 2026: The Dawn of AI-Driven Drug Development

    The article discusses the transformative role of AI in drug development, particularly in clinical trials, as highlighted at the 44th Annual J.P. Morgan Healthcare Conference. It contrasts Moore's Law, which drives technological advancement, with Eroom's Law, which reflects rising drug development costs. The focus is on oncology as a key area for AI application, with significant investments from major pharmaceutical companies. The adoption of agentic AI is expected to improve clinical trial success rates and operational efficiency, with predictions of over 200 AI-enabled drug approvals by 2030.

    Yicai·
    Yicai·

    Ascletis starts Phase II study with ASC30 in US for diabetes treatment. Expect data in Q3 2026. ASC30 shows up to 7.7% weight loss in 13-week study with overweight individuals.

    In the third quarter of 2026, the Phase II study for diabetes treatment is anticipated to reveal its topline data. The ASC30 showed promising results with a placebo-adjusted weight loss of a maximum of 7.7% in a 13-week U.S. Phase II study involving individuals struggling with obesity or being overweight. This indicates a significant improvement in managing weight-related issues.

    Unusual Whales·
    US
    SBIO
    -3.01%
    US
    PBE
    -1.52%
    US
    FBT
    -1.17%
    Unusual Whales·
    US
    SBIO
    -3.01%
    US
    PBE
    -1.52%
    US
    FBT
    -1.17%

    Study by RTI International shows significant variation in Medicaid patient retention rates in opioid treatment programs, indicating room for quality enhancement.

    A recent study conducted by experts at RTI International, an independent scientific research organization based in Research Triangle Park, North Carolina, has been published in JAMA Network Open. The study focuses on opioid treatment programs and their level measures of retention. The findings indicate opportunities for quality improvement in these programs. The report was released on January 23, 2026. For more information, interested individuals can access the study published in JAMA Network Open.

    Unusual Whales·
    Unusual Whales·

    Insilico Medicine gets FDA approval for ISM8969, NLRP3 inhibitor. Phase I trial in US to assess safety, tolerability.

    Approval of the Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) has opened the door for the ISM8969 clinical trial in the United States. This Phase I study is set to assess the safety, tolerability, and pharmacokinetics of ISM8969, a new oral therapeutic. The approval marks an important milestone, allowing the trial to move forward and potentially benefit patients.

    Unusual Whales·
    HK
    03696
    -9.50%
    Unusual Whales·
    HK
    03696
    -9.50%

    "Hong Kong Stocks" The Hang Seng Index rose 88 points in the half-day, with Alibaba and Xiaomi gaining, and POP MART rising over 6%

    The Hong Kong stock market rose in the morning session, with the Hang Seng Index up 88 points, reporting at 26,718 points. Alibaba supports its subsidiary chip company to go public, with its stock price rising by 2.6%. POP MART's stock price surged over 6% due to the release of Valentine's Day limited edition products. Xiaomi announced a share repurchase plan of 2.5 billion yuan, with its stock price rising by 2.5%. The total trading volume of the market for the half-day reached 127.938 billion yuan

    AASTOCKS·
    HK
    01810
    -2.81%
    HK
    09992
    -0.91%
    US
    BABA
    -2.23%
    AASTOCKS·
    HK
    01810
    -2.81%
    HK
    09992
    -0.91%
    US
    BABA
    -2.23%
    © 2026 Longbridge｜Disclaimer